glp 1 and joint pain Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? GLP-1 Drugs May Influence Joint

Supplier of assay kits, antibodies, biochemicals, and proteins and provider of contract research services

Prusogliptin , developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by National Medical Products Administration (NMPA) on January 8, 2025

Phase 3 enrollment is currently in progress

Puigb et al

It is also available in supplement form and is sometimes used for various health purposes

Contact a healthcare professional if you experience: Severe or persistent nausea, vomiting, or stomach pain Intense dizziness or fainting Skin rash that worsens or spreads Difficulty breathing or swelling of the face or throat For personalized advice, consider using Doctronic.ai